𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Serum ferritin and the risk of hepatocellular carcinoma in chronic liver disease of viral etiology: A case–control study

✍ Scribed by Patil, Prachi S.; Mohandas, K. M.; Bhatia, Shobna J.; Mehta, Shaesta A.

Book ID
121330156
Publisher
Springer-Verlag
Year
2013
Tongue
English
Weight
249 KB
Volume
33
Category
Article
ISSN
0254-8860

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Increased serum ferritin in chronic live
Increased serum ferritin in chronic liver disease: A risk factor for primary hepatocellular carcinoma
✍ Hie-Won L. Hann; Chung Yong Kim; W. Thomas London; Baruch S. Blumberg 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 514 KB

Previous studies from this laboratory support the view that increased serum ferritin levels are associated with an increased risk of primary hepatocellular carcinoma (PHC). We have tested this hypothesis in a population of Korean patients with chronic liver disease followed for development of PHC. S

Liver cancer in Thailand. II. A case-con
Liver cancer in Thailand. II. A case-control study of hepatocellular carcinoma
✍ Petcharin Srivatanakul; D. Maxwell Parkin; Myriam Khlat; Dhirapol Chenvidhya; Po 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 537 KB

Potential risk factors for hepatocellular carcinoma were investigated in a case-control study among inhabitants of north east Thailand. Sixty-five cases from 3 hospitals, with matched controls, were included. Infection with hepatitis-B virus was the major risk factor-chronic carriers of HB surface a

A case-control study of hepatitis B and
A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma
✍ Stephanos Hadziyannis; Edward Tabor; Evangclia Kaklamani; Anastasia Tzonou; Sher 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 563 KB

During a I 6-month period in I99 I -1992, blood samples and questionnaire data were obtained from 65 incident cases of hepatocellular carcinoma (HCC) as well as from 2 control groups of hospitalized patients matched on gender and age, which included 65 metastatic liver cancer (MLC) patients and 65 p